FUNDA ŞIMŞEK et al. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Turkish Journal of Gastroenterology, [S. l.], v. 31, n. 4, p. 305–317, 2020. Disponível em: https://tjg.avesjournals.com/index.php/tjg/article/view/3881. Acesso em: 16 jul. 2025.